An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family.

This transcytotic behavior has not previously been reported for anti-integrin antibodies. Further studies should be undertaken to validate this new mechanism in vivo and to evaluate its potential in brain delivery.